Improvement of mouth functional disability in systemic sclerosis patients over one year in a trial of fat transplantation versus adipose-derived stromal cells [PDF]
, 2016 Background. Systemic sclerosis (SSc) is a multisystem disease characterized by cutaneous and visceral fibrosis. Face and mouth changes include telangiectasia, sicca syndrome, and thinning and reduction of mouth width (microcheilia) and opening ...
CARELLA, SARA +5 more
core +4 more sources
From Localized Scleroderma to Systemic Sclerosis: Coexistence or Possible Evolution
Dermatology Research and Practice, 2018 Background. Systemic sclerosis (SSc) and localized scleroderma (LoS) are two different diseases that may share some features. We evaluated the relationship between SSc and LoS in our case series of SSc patients. Methods.
Giuggioli Dilia +5 more
doaj +1 more source
Exploring Sources of Emotional Distress among People Living with Scleroderma: A Focus Group Study. [PDF]
PLoS ONE, 2016 BACKGROUND:Systemic sclerosis, or scleroderma, is a chronic and rare connective tissue disease with negative physical and psychological implications. Sources of emotional distress and the impact they have on the lives of people with scleroderma are not ...
Stephanie T Gumuchian +13 more
doaj +1 more source
Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis. [PDF]
, 2017 BACKGROUND: Gastrointestinal tract (GIT) involvement is a common cause of debilitating symptoms in patients with systemic sclerosis (SSc). There are no disease modifying therapies for this condition and the treatment remains symptomatic, largely owing to
Abraham +105 more
core +2 more sources
Localized scleroderma: clinical spectrum and therapeutic update [PDF]
Anais Brasileiros de Dermatologia, 2015 Scleroderma is a rare connective tissue disease that is manifested by cutaneous sclerosis and variable systemic involvement. Two categories of scleroderma are known: systemic sclerosis, characterized by cutaneous sclerosis ...
Mariana Figueiroa Careta, Ricardo Romiti
doaj +2 more sources
Assessment of tissue fibrosis in skin biopsies from patients with systemic sclerosis employing confocal laser scanning microscopy: an objective outcome measure for clinical trials? [PDF]
, 2010 OBJECTIVES: To obtain an objective, unbiased assessment of skin fibrosis in patients with SSc for use in clinical trials of SSc disease-modifying therapeutics.
Busquets, Joanna +3 more
core +3 more sources
Checkpoint Inhibitor-Associated Scleroderma and Scleroderma Mimics
Pharmaceuticals, 2023 Immune checkpoint inhibitors (ICI) are the standard of care for various malignancies and have been associated with a wide spectrum of complications that are phenotypically akin to primary autoimmune diseases.
Michael Macklin +3 more
doaj +1 more source
A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. [PDF]
, 2012 OBJECTIVE: A prospective observational study of mycophenolate mofetil (MMF) treatment in patients with diffuse progressive cutaneous systemic sclerosis (SSc) of recent onset.
Jimenez, Sergio A. +3 more
core +3 more sources
Scleroderma with crescentic glomerulonephritis: a case report
Journal of Medical Case Reports, 2008 Introduction Systemic sclerosis or scleroderma is an autoimmune rheumatic disease characterized by organ-based fibrosis. Renal involvement in scleroderma occurs mainly in the form of scleroderma renal crisis, affecting 5 to 10% of patients.
Ramaswami Arunachalam +8 more
doaj +1 more source
Angiogenic and angiostatic factors in renal scleroderma-associated vasculopathy [PDF]
, 2017 BACKGROUND: The angiogenesis in systemic sclerosis (SSc) is impaired. An imbalance of pro-angiogenic factors and angiogenesis inhibitors has been implicated in the progression of peripheral microvascular damage, defective vascular repair and fibrosis ...
Afeltra, Antonella M. Vittoria +7 more
core +1 more source